FX-322

DRUG5 trials

Sponsors

Frequency Therapeutics

Conditions

Hearing LossHearing Loss, SensorineuralNoise Induced Hearing LossPresbycusisSensorineural Hearing LossSudden Hearing Loss

Early Phase 1

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

CompletedNCT03300687

Frequency TherapeuticsHearing Loss

Start: 2017-05-30End: 2018-01-18Updated: 2018-04-12

Phase 1

FX-322 in Sensorineural Hearing Loss

CompletedNCT03616223

Frequency TherapeuticsSensorineural Hearing Loss

Start: 2018-07-03End: 2018-12-18Updated: 2022-11-14

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

CompletedNCT04601909

Frequency TherapeuticsHearing Loss, Sensorineural, Noise Induced Hearing Loss, Presbycusis +1

Start: 2020-09-17End: 2022-05-16Updated: 2022-05-25

FX-322 in Adults With Severe Sensorineural Hearing Loss

CompletedNCT04629664

Frequency TherapeuticsHearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss

Start: 2020-11-02End: 2021-09-20Updated: 2022-02-01

Phase 2

FX-322 in Adults With Acquired Sensorineural Hearing Loss

CompletedNCT05086276

Frequency TherapeuticsHearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss

Start: 2021-10-12End: 2022-12-30Updated: 2023-04-21